Is GSK part of Novartis?
Basel, June 1, 2018 – Novartis AG (“Novartis”) today announced the completion of the divestment to GlaxoSmithKline PLC (“GSK”) of its 36.5 percent stake in a consumer healthcare joint venture (JV) for a total consideration of USD13. 0 billion.
When did GSK buy Novartis?
On March 27, British pharmaceutical company GlaxoSmithKline (GSK) announced it bought out Switzerland-based Novartis’ stake in their joint consumer healthcare venture. GSK will now own 100 percent of the business, whose products include Panadol painkillers, Sensodyne toothpaste and Voltarol muscle gel.
Is Pfizer buying GSK?
Company Deals On July 31, 2019, Pfizer Inc. (“Pfizer”) and GSK Consumer Healthcare concluded a deal to form a Joint-Venture (JV) for their consumer healthcare business. As a part of deal, GSK held majority controlling equity interest of 68% in the JV and the rest 32% equity interest was owned by Pfizer.
What are the main products of GSK?
The largest selling GSK products are Seretide/Advair for asthma and Chronic Obstructive Pulmonary Disease (COPD); Paxil/Seroxat and Wellbutrin, both anti-depression drugs; Avandia/Avadamet for type 2 diabetes; and the antibiotic Augmentin.
Does Roche own Novartis?
Novartis has been a shareholder of Roche since May, 2001 and currently holds 53.3 million bearer shares of Roche’s common stock, representing approximately 33% of aggregate outstanding bearer shares.
Who is the owner of Novartis?
Geigy President Louis von Planta and CIBA President Robert Käppeli shake hands to conclude the merger of CIBA-GEIGY in 1970. In 1996, the merger of Sandoz and Ciba-Geigy creates Novartis, one of the world’s largest healthcare companies.
Does Novartis own Voltaren?
GSK acquired Novartis’ portfolio of Voltaren products in March 2016 and has been responsible for marketing and selling Voltaren products since 1 June 2016, after a 3 month transitional period. GSK is one of the largest suppliers of over-the-counter analgesic products in Australia.
What drugs have GSK made?
A-Z list of our global medicines portfolio
| Trademark | Generic |
|---|---|
| Amoxil | amoxicillin |
| Anectine | suxamethonium chloride |
| Anoro Ellipta | umeclidinium and vilanterol |
| Augmentin | amoxicillin/clavulanate potassium |
How much did Novartis pay for GSK oncology products?
GSK oncology products. Novartis has acquired GSK’s oncology products, including two pipeline candidates, for an aggregate cash consideration of USD 16 billion. Up to USD 1.5 billion of this amount is contingent on certain development milestones.
What are the names of GSK’s oncology drugs?
GSK’s marketed Oncology portfolio comprises the rights to GSK’s currently marketed oncology assets (Votrient, Arzerra, Promacta/Revolade, Tykerb/Tyverb, Tafinlar, Mekinist, Arranon, Hycamtin, Zofran, Argatroban and Alkeran). Also being sold to Novartis are the rights to GSK’s AKT inhibitor, currently in development.
What did GlaxoSmithKline do with Novartis AG?
GlaxoSmithKline plc today announces a major three-part inter-conditional transaction with Novartis AG involving its Consumer Healthcare, Vaccines and Oncology businesses Issued: London UK – LSE announcement
What was the sales of GSK in 2014?
Sales of the acquired GSK oncology products in 2014 were approximately USD 2.0 billion and grew approximately 32% in local currency against 2013.*